Filtern
Erscheinungsjahr
- 2016 (5) (entfernen)
Dokumenttyp
- Vortrag (3)
- Posterpräsentation (2)
Referierte Publikation
- nein (5)
Schlagworte
- Bioactive (3)
- Crystallization (3)
- Glass (3)
- Sintering (3)
- Bioaktiv (2)
- Glas (2)
- Kristallisation (2)
- Sintern (2)
- Korngröße (1)
Eingeladener Vortrag
- nein (3)
Bioaktive Gläser werden zur Knochenregeneration derzeit überwiegend in Form von Pulvern oder Pasten einge-setzt. Gesinterte Strukturen oder Fasergewebe werden hingegen bisher kaum klinisch genutzt. Grund hierfür sind die gegenläufigen Tendenzen von Prozessierbarkeit und Bioaktivität. Beim kommerziell etablierten Bioglass® 45S5 wird eine vollständige Sinterung durch Kristallisation verhindert. Aus diesem Grund war es das Ziel, neue Glaszusammensetzungen zu entwickeln, welche gleichermaßen eine gute Prozessierbarkeit und eine hohe Bioak-tivität aufweisen. Ausgehend vom Bioglass® 45S5 (SiO2-P2O5-CaO-Na2O) wurde das Calcium / Alkali-Verhältnis angehoben, Natriumoxid teilweise durch Kaliumoxid ersetzt und bis zu 8 mol% Calciumfluorid hinzugefügt, um dessen Tendenz zur Kristallisationsneigung zu verringern. Das Sinter- und Kristallisationsverhalten der neuen Gläser und der Einfluss der Korngrößenverteilung wurden mittels Partikelgrößenanalyse, Erhitzungsmikroskopie DTA, DSC, FTIR, XRD und REM untersucht. Die Ergebnisse zeigen, dass die neuentwickelten Gläser ein deutlich verbessertes Sinterverhalten aufweisen und relative Dichten von 88 – 99 % erreichen. Dagegen konnten vergleichbare Bioglass® 45S5 -Pulver nur bis auf 57 – 67 % gesintert werden. Diese Beobachtung sowie XRD- und FTIR-Messungen belegen, dass Bioglass® 45S5 bereits während des Sinterns kristallisiert wogegen die neu entwickelten Gläser erst nach dem vollständigen Verdichten kristallisieren.
Bioglass® 45S5 is mainly used clinically as powders, granules or pastes instead of sintered compacts. This is due to the inherent problem of crystallization during sintering. Recently, new bioactive glasses with improved crys-tallization stability have been developed as promising candidates for manufacturing of sintered powder compacts for bone regeneration, which combine improved sintering behavior with bioactivity. Compared with the well-known Bioglass® 45S5 (SiO2-P2O5-CaO-Na2O) the calcium/alkali oxide ratio was increased, sodium oxide was partially replaced by potassium oxide and up to 3 mol% calcium fluoride were added, in order to stabilize the glass against crystallization. Sintering and crystallization were characterized by heating microscopy, XRD, FTIR, SEM, and DTA. The results show that a sintered density of 88-99 % is achieved in contrast to only 57-67% for Bioglass® 45S5. Whereas Bioglass® 45S5 powder compacts crystallize during sintering, for the new glasses no crystalline phases were detected. Additionally the influence of grain size was characterized. These studies showed that full densification can be attained for particle size < 32 µm, whereas coarser particles pro-gressively increase residual porosity. Observed foaming phenomena, are strongly retarded by crystallization.
Nowadays, the use of bioactive glasses is established for bone regeneration; however glasses are used mostly as powders, granules or in a paste. Sintered scaffolds are not used clinically, because of the inherent problem of crystallization during the sintering process, resulting in poor mechanical properties and reduced bioactivity. Therefore it was the aim to design new bioactive glasses, which combine improved processing and sintering with bioactivity.
Compared with the well-known Bioglass® 45S5 (SiO2-P2O5-CaO-Na2O) the calcium/alkali oxide ratio was increased, sodium oxide was partially replaced by potassium oxide and up to 8 mol% calcium fluoride were added, in order to stabilize the glass against crystallization.
The sintering behavior of the new glasses was characterized by heating microscopy and compared to that of Bioglass® 45S5. Results show that the new glasses achieve a sintered density of 88-99 % in contrast to only 57-67% for Bioglass® 45S5. In addition, FTIR and XRD analyses show that Bioglass® 45S5 crystallizes during sintering while for the new glasses no crystalline phases were detected. The thermal properties of all glasses were studied by DTA and DSC measurements, and the influence of grain size was characterized. These studies showed an increase of sintering temperature and final porosity with increasing particle size. The structure of sintered compacts during and after sintering was examined using light and electron microscopy (SEM).
Bioglass® 45S5 is mainly used clinically as powders, granules or pastes instead of sintered compacts. This is due to the inherent problem of crystallization during the sintering, which results in poor mechanical properties and reduced bioactivity. Recently, new bioactive glasses with improved crystallization stability have been developed as promising candidates for manufacturing of sintered powder compacts for bone regeneration, which combine improved sintering behavior with bioactivity. Compared with the well-known Bioglass® 45S5 (SiO2-P2O5-CaO-Na2O) the calcium/alkali oxide ratio was increased, sodium oxide was partially replaced by potassium oxide and up to 3 mol% calcium fluoride were added, in order to stabilize the glass against crystallization. The aim of this study was to investigate the sintering and crystallization behavior of these new bioactive glasses.
Sintering and crystallization were characterized by heating microscopy, XRD, FTIR, SEM, and DTA. The results show that a sintered density of 88-99 % is achieved in contrast to only 57-67% for Bioglass® 45S5. In addition, FTIR and XRD analyses show that Bioglass® 45S5 crystallized during sintering while for the new glasses no crystalline phases are detected. The thermal properties of all glasses were studied by DTA measurements, and the influence of grain size was characterized. These studies showed that full densification can be attained for particle size < 32 µm, whereas coarser particles progressively increase residual porosity. Observed foaming phenomena, are strongly retarded by crystallization of beta-HAp.